Journal article icon

Journal article

Impact on Medical Cost, Cumulative Survival, and Cost-Effectiveness of Adding Rituximab to First-Line Chemotherapy for Follicular Lymphoma in Elderly Patients: An Observational Cohort Study Based on SEER-Medicare.

Abstract:

Rituximab improves survival in follicular lymphoma (FL), but is considerably more expensive than conventional chemotherapy. We estimated the total direct medical costs, cumulative survival, and cost-effectiveness of adding rituximab to first-line chemotherapy for FL, based on a single source of data representing routine practice in the elderly. Using surveillance, epidemiology, and end results (SEER) registry data plus Medicare claims, we identified 1,117 FL patients who received first-line C...

Expand abstract

Actions


Access Document


Publisher copy:
10.1155/2012/978391

Authors


Griffiths, RI More by this author
Gleeson, ML More by this author
Mikhael, J More by this author
Danese, MD More by this author
Journal:
Journal of cancer epidemiology
Volume:
2012
Pages:
978391
Publication date:
2012
DOI:
EISSN:
1687-8566
ISSN:
1687-8558
URN:
uuid:8c713685-ecca-4b83-8f1b-e813b9a95bfd
Source identifiers:
359092
Local pid:
pubs:359092
Language:
English

Terms of use


Metrics



If you are the owner of this record, you can report an update to it here: Report update to this record

TO TOP